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ABSTRACT 
Introduction 
Hodgkin lymphoma (HL) is a malignancy of lymphoid cells that was first described by Thomas 
Hodgkin in 1832. It is recognized histologically by the presence of the characteristic Reed-
Sternberg cells, bathed in a reactive cellular background of inflammatory cells. Hodgkin 
lymphoma is less common than Non-Hodgkin Lymphoma (NHL) and accounts for 
approximately 10-20 % of all the lymphomas encountered. It is most often seen in young adults, 
with a peak frequency in the third decade of life. 
Hodgkin lymphoma is characterized by the orderly spread of disease from one lymph node 
group to another (contiguous spread and centripetal distribution) and by the development of 
systemic symptoms, particularly with advanced stage disease. True extra nodal disease is 
uncommon. 
 
Pathologically, Hodgkin lymphoma is categorized into two groups: Nodular lymphocyte 
predominant Hodgkin lymphoma which accounts for about 5% and Classical Hodgkin 
lymphoma which accounts for 95%. Classical Hodgkin lymphoma is further subdivided into 
four subtypes: Nodular sclerosis classical Hodgkin lymphoma, Mixed cellularity classical 
Hodgkin lymphoma, Lymphocyte rich classical Hodgkin lymphoma and Lymphocyte depleted 
classical Hodgkin lymphoma.  
Once the diagnosis is confirmed on a lymph node or tissue biopsy, a complete work up is done, 
which includes blood investigations, a bone marrow aspirate and biopsy and appropriate 
radiological investigations. Following on this, the treatment is individualized and includes both 
supportive care and specific therapy. The specific initial treatment of Hodgkin lymphoma 
involves combination chemotherapy and where necessary involved field radiotherapy. Cure is 
a realistic goal in more than 90% of patients with early stage disease.  A delicate balance exists 
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between optimal initial treatment and the development of late complications of the disease, 
mainly related to treatment. 
 
The last decade has witnessed the emergence of Hodgkin lymphoma occurring with increasing 
frequency in association with the Human Immunodeficiency virus (HIV) infection. The relative 
risk is 10-20 fold higher with HIV seropositivity, compared to the general population. HIV 
associated Hodgkin lymphoma is generally more aggressive, presents with advanced stage 
disease, frequent ‘B’ symptoms, less favorable histology, more frequent bone marrow 
involvement and overall a poorer prognosis compared to Hodgkin lymphoma in HIV 
seronegative individuals.  
 
This study was aimed at exploring and defining the changing pattern of Hodgkin lymphoma at 
Chris Hani Baragwanath Academic Hospital (CHBAH) from January 2005 to December 2012. 
Other objectives were to review: (i) the impact of HIV on the clinical pattern of disease and 
(ii) the different treatment options and the outcome of the patients. 
 
Patients and Methods  
This was a retrospective review of all adult patients with Hodgkin lymphoma seen at the 
Clinical Hematology Unit, Department of Medicine from January 2005 to December 2012 at 
CHBAH. Descriptive analysis was conducted through the computation of frequency tables for 
categorical variables and appropriate measures of central tendency i.e. mean ± SD/median 
(IQR) for continuous variables. Kaplan Meier survival curves were plotted to determine the 
survival probability of the patients based on demographic and clinical characteristics.  
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Results 
A total of 150 patients with a confirmed diagnosis were included in the study. Ninety three 
percent of the patients were of black ethnicity. There were 84 males (56%) and 66 females 
(44%), with a male to female ratio of 1.27:1. The median age of the patients was 37 years, with 
a peak frequency in the third and fourth decades of life. HIV seropositivity was noted in 90 
patients (60%), with the remaining 60 patients (40%) being seronegative. For the whole group 
of 150 patients, lymphadenopathy was the most common presenting feature (92.7%). ‘B’ 
symptoms were present in 74.7% of the patients. Advanced stage disease was noted in 74% of 
the patients and a performance status of ≥2 was evident in 66.7% of the patients. 
A comparison of the HIV seropositive and HIV seronegative patients shows that there is a 
statistically significant difference between the histological subtypes (mixed cellularity with 
HIV seropositivity and nodular sclerosis with HIV seronegativity), TB association (higher with 
HIV seropositivity) and more bone marrow involvement with HIV seropositivity. However, 
the median survival was shorter in HIV seropositive compared to HIV seronegative individuals.  
 
Conclusion 
As compared to the current literature on Hodgkin lymphoma (particularly from the developed 
world), our study showed a high prevalence of HIV and TB, in association with Hodgkin 
lymphoma. There is a paradigm shift at our institution, from an early period in the 1980’s with 
no HIV seropositivity in association with HL, to <50% in the 1990’s and early 2000’s, to > 
50% in the last decade. The association between HIV and HL has an impact on the clinical 
presentation and outcome of the patients.  Therefore, health care workers need to be aware of 
this emerging and increasing association between HIV and Hodgkin lymphoma.  
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1.0 CHAPTER ONE: LITERATURE REVIEW 
1.1 INTRODUCTION 
Hodgkin Lymphoma (HL) is a malignancy of lymphoid cells that was first described by Thomas 
Hodgkin and Samuel Wilks in 1832 (1). Three autopsy specimens from the initial suspected seven 
cases of Hodgkin Lymphoma (HL) were preserved in alcohol until 1998, when Poston proved that 
two of the three preserved cases were confirmed cases of Hodgkin Lymphoma (HL) as evidenced 
by the presence of the classic Reed-Sternberg (RS) cells and its associated marker, CD15 (2, 3). 
Hodgkin Lymphoma (HL) was referred to as lymphogranulomatosis and Hodgkin’s disease. 
However, with the presence of Reed-Sternberg (RS) cells which are of lymphoid origin and are 
now known to be clonal, the preferred term is Hodgkin Lymphoma (1).  
 
1.1.1 PATHOGENESIS OF HODGKIN LYMPHOMA  
Hodgkin Lymphoma (HL) was first described in 1832. However, it was not until recently that its 
pathogenesis has become better understood. Diagnostic techniques such as immunophenotyping, 
cytogenetic and molecular profiling have provided new insights into the pathogenesis of Hodgkin 
Lymphoma (HL). Hodgkin-Reed-Sternberg (H-RS) cells are the diagnostic tumour cells in classic 
Hodgkin Lymphoma (cHL) and are of  B-cell origin (4, 5). Hodgkin-Reed-Sternberg (H-RS) cells 
are derived from the germinal centre and have clonally rearranged but “crippled” immunoglobulin 
genes. The cells have lost their capacity to express a high-affinity B-cell receptor and escape 
negative selection (4, 5).  
Several aberrantly activated signalling pathways and transcription factors have been identified that 
contribute to the rescue of Hodgkin-Reed-Sternberg (HR-S) cells from natural apoptosis. It is 
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believed that execution of apoptosis is prevented in germinal centre B cells by up-regulation of an 
inhibitor called c-FLIP (an inhibitor of FAS-mediated apoptosis). Also, high levels of the nuclear 
transcription factor-k– (NF-k) have been found in H-RS cells; these high NF-k levels may play a 
role in the pathogenesis by interfering with apoptosis. Epstein Barr virus (EBV) is linked to the 
development of HL because it is believed that EBV possesses a transforming ability that leads to 
NF-k activation in antigen-activated B cells  (4, 5) . 
1.1.2 CLASSIFICATION OF HODGKIN LYMPHOMA 
The first histological classification of Lymphoma (including Hodgkin lymphoma) was described 
by Jackson and Parker in 1944. This was used until 1964 when it was replaced by the Lukes and 
Butler classification. The Lukes and Butler classification was later simplified at the Rye 
conference in 1965, and has been used for over 30 years due to its good clinical and pathological 
correlation. The Rye classification was based on histology and consists of four subtypes: mixed 
cellularity, nodular sclerosis, lymphocyte rich and lymphocyte depleted subtypes. However, the 
Rye classification was reviewed in the Revised European-American Lymphoma (REAL) 
classification in 1994. Hodgkin Lymphoma (HL) was then classified into two entities: 1) nodular 
lymphocyte predominant Hodgkin Lymphoma (NLPHL), and 2) classical Hodgkin Lymphoma 
(cHL) which comprises four subtypes: nodular sclerosis, mixed cellularity, lymphocyte-rich and 
lymphocyte- depleted. Currently the REAL classification still applies and has been accepted and 
adopted by the World Health Organisation (WHO). Two additional sub- groups have been 
included in the WHO classification, (i) ‘Unclassifiable HL’ that is used to describe cases where 
biopsy material is insufficient, or when the diagnosis of HL is made from an extra nodal site only  
and (ii) ‘Lymphomas with intermediate features between cHL and Diffuse Large B cell Lymphoma 
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(DLBCL)’ - previously known as grey zone lymphomas. These lymphomas have morphologic and 
phenotypic features of both cHL and DLBCL (5-7).  
 
Tab Table 1.1:  WHO classification of Hodgkin lymphoma 
-Nodular lymphocyte predominant Hodgkin lymphoma 
- Classical Hodgkin lymphoma  
          1. Nodular sclerosis classical Hodgkin lymphoma  
          2. Lymphocyte-rich classical Hodgkin lymphoma  
          3. Mixed cellularity classical Hodgkin lymphoma  
          4. Lymphocyte-depleted classical Hodgkin lymphoma  
 
 
 
 
1.1.2.1 Nodular lymphocyte predominant Hodgkin lymphoma 
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) comprises about five percent of 
all HL’s, however; there are variable estimates for the relative frequency of nodular lymphocyte-
predominant Hodgkin lymphoma in the pediatric population, ranging from 5-10%. The relative 
frequency is higher for children younger than 10 years compared with children aged 10 to 19 years. 
Patients with nodular lymphocyte-predominant Hodgkin lymphoma generally present with 
localized, non-bulky disease that infrequently involves the mediastinum (8). A proportion of 
patients may also be asymptomatic.  
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Nodular lymphocyte-predominant Hodgkin lymphoma is characterized by molecular and 
immunophenotypic evidence of B-lineage differentiation with the following distinctive features:  
o Nodular lymphocyte-predominant Hodgkin lymphoma is characterized by large 
cells with multilobed nuclei, referred to as “popcorn” cells. These cells express B-
cell antigens, such as CD19, CD20, CD22, and CD79A, and are negative for CD15 
and may or may not express CD30 (8). 
o The OCT-2 and BOB.1 oncogenes are both expressed in nodular lymphocyte-
predominant Hodgkin lymphoma; they are not expressed in the cells of patients 
with classical Hodgkin lymphoma (8). 
o Reliable discrimination from non-Hodgkin lymphoma is problematic in diffuse 
subtypes with lymphocytic and histiocytic cells set against a diffuse background of 
reactive T-cells  
o Nodular lymphocyte-predominant Hodgkin lymphoma can be difficult to 
distinguish from progressive transformation of germinal centers and/or T-cell-rich 
B-cell lymphoma (8). 
Chemotherapy and/or radiation therapy produce excellent long-term progression-free survival and 
overall survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma; however, 
late recurrences have been reported up to 10 years after initial therapy (8). 
Deaths observed among individuals with nodular lymphocyte-predominant Hodgkin lymphoma 
are more frequently related to treatment complications and/or the development of subsequent 
neoplasms (including non-Hodgkin lymphoma), underscoring the importance of judicious use of 
chemotherapy and radiation therapy at initial presentation and after recurrent disease (8). 
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 For patients with localised disease that has been fully excised, a “watch and wait” approach may 
be reasonable. Patients with localised disease also benefit from 20-30Gy of Involved field radiation 
therapy (IFRT), with the 10-year progression free survival (PFS) for stage I being 85% and 65% 
for stage II disease. Patients with more advanced disease are usually treated with combination 
chemotherapy similar to cHL. Rituximab is often added to Doxorubicin (Adriamycin), Bleomycin, 
Vinblastine, Dacarbazine (ABVD). A study of single agent Rituximab in patients with relapsed 
disease has shown an overall response rate of 94%. Trials to optimize chemotherapy (with 
Rituximab) are in progress (8). 
 
1.1.2.2 Classical Hodgkin Lymphoma (cHL) 
 
1.1.2.2.i Pathology of Classical Hodgkin Lymphoma 
The characteristic Hodgkin and Reed-Sternberg (HRS) cells in cHL, and the lymphocytic and 
histiocytic (L and H) cells in NLPHL, account for only 1% to 5% of the entire tumour mass and 
grow in a unique tumour microenvironment composed of many different cell types, including T 
cells, B cells, macrophages, neutrophils, eosinophils, plasma cells, mast cells, and fibroblasts (3). 
RS cells contain at least two nuclei, with their nucleoli occupying more than 50% of the nuclear 
area. Mononuclear variants of the RS cell also make up the neoplastic cell population. These cells, 
known as Hodgkin cells, have the same phenotype as the RS cell. The HRS cells are usually of 
germinal centre B cell origin, but have lost their B cell programming by multiple mechanisms. 
Hence, their phenotypic expression is not that of a typical B cell. More than 98% of HRS cells 
express CD30. CD15 expression has been found in approximately 80% of patients with cHL. 
CD20 is less frequently expressed (9). HRS cells do not produce immunoglobulin.  
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Although the RS cell is said to be diagnostic of cHL, its presence is not exclusive to HL. Similar 
cells may be seen in reactive lesions like infectious mononucleosis, in some non-Hodgkin’s 
lymphomas (B and T cell), carcinomas, sarcomas and melanomas (9). Hence the diagnosis of cHL 
has to be made on finding the neoplastic cells within an appropriate cellular background. 
Classical Hodgkin lymphoma is divided into the following four subtypes: 
 Lymphocyte-rich classical Hodgkin lymphoma. 
 Nodular sclerosis classical Hodgkin lymphoma. 
 Mixed-cellularity classical Hodgkin lymphoma. 
 Lymphocyte-depleted classical Hodgkin lymphoma. 
These subtypes are defined according to the number of Reed-Sternberg cells, characteristics of the 
inflammatory milieu, and the presence or absence of fibrosis. 
Although this classification is mainly based on histopathology, taking into account differences in 
the composition of the reactive infiltrate and stroma, recent studies have demonstrated that these 
disease entities are biologically different, with different genomic alterations, gene-expression 
patterns, cytokine milieu, and clinical behaviour (10).  
The epidemiology, clinical presentation, and prognosis of these subtypes are also different (10, 
11), but these differences have not yet been translated into changes in the treatment approach, since 
the Adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy 
regimen remains the mainstay for the treatment of all cHL subtypes.  
 
1.1.2.2.ii Lymphocyte-rich classical Hodgkin lymphoma 
Lymphocyte-rich classical Hodgkin lymphoma (LRcHL) may have a nodular appearance, but 
immunophenotypic analysis allows distinction between this form of Hodgkin lymphoma and 
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nodular lymphocyte-predominant Hodgkin lymphoma (12). Lymphocyte-rich classical Hodgkin 
lymphoma cells express CD15 and CD30, while nodular lymphocyte-predominant Hodgkin 
lymphoma almost never expresses CD15.  
 
1.1.2.2.iii Nodular sclerosis classical Hodgkin lymphoma 
Nodular sclerosis classical Hodgkin lymphoma (NScHL) affects young adults and is more 
common in females. It frequently involves the mediastinum, which comprises the tissues and 
organs of the chest excluding the lungs. It is less frequently associated with Epstein-Barr virus 
(EBV) infection and probably requires an intact immune system to develop. The incidence in HIV-
positive patients appears to be less as the number of CD4+ lymphocytes declines (13). Several 
studies using gene-expression profiling and expression of surface markers have suggested a link 
between mediastinal NScHL and primary mediastinal B-cell lymphoma. In contrast, MCcHL and 
LDcHL have epidemiological and clinical features that are distinct from NScHL: they are more 
frequent in males, have a bimodal age distribution, are frequently associated with EBV and HIV 
infection, and normally spare the mediastinum. The prognosis for MCcHL and LDcHL is worse 
than for NScHL (2). LRcHL is characterized by older age at presentation, infrequent mediastinal 
involvement, and excellent prognosis (12) . NScHL is distinguished by the presence of fibrous or 
collagenous bands that divide the lymph node into nodules. In addition, a Reed-Sternberg cell 
variant called the lacunar cell may be present (clear area around the RS cell, due to a retraction 
staining artefact). 
Some pathologists subdivide nodular sclerosis into two subgroups (NS-1 and NS-2) on the basis 
of the number of Reed-Sternberg cells present. Transforming growth factor-beta may be 
responsible for the fibrosis in the nodular sclerosis Hodgkin lymphoma subtype.  
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A study of over 600 patients with nodular sclerosis Hodgkin lymphoma from three different 
university hospitals in the United States showed that two haplotypes in the HLA class II region 
were identified (HLA-DQA1 and DQB1) , which correlated with 70% increased risk of developing 
nodular sclerosis Hodgkin lymphoma (8). Another haplotype (DRB1) was associated with a 60% 
decreased risk. It is hypothesized that these haplotypes result in atypical immune responses that 
lead to Hodgkin lymphoma (8). 
 
1.1.2.2.iv Mixed-cellularity classical Hodgkin lymphoma 
Mixed-cellularity classical Hodgkin lymphoma (MCcHL) is more common in young children than 
in adolescents and adults. MCcHL accounts  for approximately 20% of cases in children younger 
than 10 years, but only  9% of older children and adolescents aged 10 to 19 years in the United 
States (12). It is however, the most common subtype in patients with HL in developing countries. 
Reed-Sternberg cells are frequent in a background of abundant normal reactive cells (lymphocytes, 
plasma cells, eosinophils, and histiocytes). Interleukin-5 may be responsible for the eosinophilia 
in mixed-cellularity Hodgkin lymphoma. This subtype can be confused with non-Hodgkin 
lymphoma. Mixed-cellularity Hodgkin lymphoma is more common in patients with Human 
immunodeficiency virus (HIV) infection (10, 14). 
1.1.2.2.v Lymphocyte-depleted classical Hodgkin lymphoma 
 
Lymphocyte-depleted classical Hodgkin lymphoma (LDcHL) is rare in children but appears to be 
common in adults with HIV (although much less common than MCcHL and NScHL). This subtype 
is the rarest variant and is characterized by the presence of numerous large, bizarre malignant cells, 
many Reed-Sternberg cells, and few lymphocytes. Diffuse fibrosis and necrosis are common. 
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Many cases previously diagnosed as lymphocyte-depleted Hodgkin lymphoma are now recognized 
as diffuse large B-cell lymphoma, anaplastic large-cell lymphoma, or nodular sclerosis classical 
Hodgkin lymphoma with lymphocyte depletion  It has the worst prognosis (8). 
 
 
1.1.3 The Reed – Sternberg Cell  
These are large cells (30 to 50 microns in diameter), and are either multinucleated or have a bilobed 
nucleus with prominent eosinophilic inclusion like nuclei. Reed Sternberg cells (HRS) are CD15 
and CD30 positive, and are usually CD20 and CD 45 negative. HRS is capable of survival and 
unrestricted tumour growth. There are two factors which help the HRS neoplastic capacity: 
Apoptosis deregulation and constitutive NFkB activity. HRS also expresses C-FLIP which helps 
down regulate Fas and evades apoptosis. NFkB activity is enhanced by CD40 ligand and latent 
membrane potential (LMP-1) inhibitor of kappa kinase B (IkB). There may also be defects in IkB. 
The end result is activation of transcription factors that prevent apoptosis of HRS (14, 15). 
 
1.1.4 The role of Epstein Barr Virus (EBV) 
Epstein Barr Virus (EBV) has been implicated in the pathogenesis of HL with a frequency of 15 
to 50% in the immunocompetent host. An association of EBV with HL is significant in 
immunocompetent patients with cHL and in HIV patients with HL. EBV has an integration rate of 
20-80% into the HRS genome. The exact role of EBV in the pathogenesis of HL is unknown. 
However, LMP-1 has oncogenic potential by enhancing bcl 2 expression and by acting via the 
CD40 signalling pathway to evade apoptosis of HRS cells (16-18). 
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1.2 Epidemiology of Hodgkin Lymphoma 
Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that affects the B-
lymphocytes. Estimates suggest that around 1 in 25,000 people are affected by this malignancy 
every year and the condition accounts for less than 1% of all malignancies that occur worldwide. 
Although HL can affect people of any age, it generally develops among two age groups: in 
particular, those aged between 15 and 35 years and those aged over 55 years. In the younger age 
group and in females, the nodular sclerosis subtype is more common, while people in the older age 
group are more commonly affected by the mixed cellularity subtype (19).  
Hodgkin lymphoma (HL) is also more common among people with HIV infection, compared to 
the general population. In contrast to what is observed for the other forms of lymphoma associated 
with HIV, HL tends to develop among patients with HIV who have a higher CD4 T-cell count 
(19). 
According to the American Cancer Society, estimates for the United States suggest that in 2014, 
around 9,190 new cases of HL were diagnosed, involving 4,120 females and 5,070 males.  
Hodgkin lymphoma is one of the most curable malignancies, with the 1-year survival rate being 
in the range of 90% to 95% (19). 
Hodgkin Lymphoma (HL) accounts for approximately 10% of all lymphomas. The pattern of age-
specific incidence differs by geographic location and appears to parallel the level of industrial 
development: 
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 In economically advantaged countries, there is one peak in young adults 
(approximate age - 20 years) and one in adults of older age (approximate age - 65 
years).  However, the majority of patients are young adults. 
 In economically disadvantaged areas; there is an initial peak in childhood for boys, 
relatively low rates in young adults, and a late peak in older adults (20, 21). 
The predominant histologic subtype also differs by geographic location and economic 
advancement. In developed countries such as the US, nodular sclerosis classical HL (NScHL) is 
the predominant histologic subtype and accounts for most disease in young adults. In economically 
disadvantaged areas, mixed cellularity classical HL (MCcHL) is more frequent in children and 
older adults. Early industrialized or transitional economies tend to have roughly equal frequencies 
of the MCcHL and NScHL subtypes (20, 21). 
In the US and Europe, the approximate percentage of classic HL cases from each subgroup are as 
follows (20). 
 Nodular sclerosis classical HL (70 percent) 
 Mixed cellularity classical HL (20 to 25 percent) 
 Lymphocyte rich classical HL (5 percent) 
 Lymphocyte depleted classical HL (less than 1 percent) 
In a local study done at CHBAH, the proportions of histological subtypes found were as follows:  
 Nodular sclerosis classical HL 37% 
 Mixed cellularity classical HL 45% 
 Lymphocyte rich classical HL 0% 
 Lymphocyte depleted classical HL 0% (21). 
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Risk factors as shown by the above study include: Socioeconomic status and the environment, 
immunosuppression, autoimmune disorders and risk in family members (21). 
 
1.3 Clinical features of Hodgkin Lymphoma 
Hodgkin lymphoma (HL) can present in various ways with slight differences depending on the 
immune status, age, histological subtypes and geographical area (20-21). 
Hodgkin lymphoma (HL) commonly presents with painless enlarging lymph nodes which may 
wax and wane. Approximately 90% of the lymph nodes are supradiaphragmatic lymph nodes, 
mostly in the cervical region (22-23). 
Less commonly lymphadenopathy may present in sub diaphragmatic sites only (mostly in older 
patients). The pattern of disease spread is highly predictable, with contiguous spread to the 
centriaxial lymph nodes being typical. Therefore, mediastinal lymph nodes are commonly affected 
(23). There may also be infiltration of organs such as the liver, spleen, bone marrow and lungs. 
However,  a patient may also present with local organ specific symptoms such as cough and bone 
pain as well as deranged laboratory tests or non-specific constitutional symptoms (23) . 
In Hodgkin lymphoma (HL), up to one third of patients experience at least one constitutional 
symptom or ‘B’ symptom (22). Constitutional symptoms correlate with more advanced stage 
disease, bulky disease and poor prognosis. Constitutional symptoms include: weight loss of >10% 
body weight in the preceding six months, unexplained fever and drenching night sweats. The 
diagnosis of HL may be challenging due to the fact that some patients may present with 
constitutional symptoms only, for which there is a broad differential diagnosis. Non-specific 
symptoms include pruritis and alcohol induced lymph node pain. Pruritis has been described in up 
to 30% of patients with HL (3). 
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There are two types of extra nodal involvement by HL. These include: 1) Direct local extension 
from involved lymph nodes or via adjacent lymphatics, which is common e.g. involvement of 
adjacent pleura, pericardium, skin etc. and 2) Distant extra nodal spread, usually to four main 
organs: the bone marrow, liver, lung and bone. Distant involvement of extra nodal sites such as 
the brain and gastrointestinal tract is extremely unusual and the diagnosis should be confirmed 
with tissue biopsy in such cases. Even in HIV positive individuals with HL, true extra nodal disease 
(excluding liver, spleen and bone marrow) is most uncommon. 
Autoimmune cytopaenias and paraneoplastic manifestations are infrequently associated with HL 
(24). Autoimmune haemolytic anaemia and autoimmune thrombocytopenia, if found to be 
associated with HL, usually resolve on treatment of HL (25). Paraneoplastic neurological 
manifestations include cerebellar disease, sub-acute myelopathy, motor neuropathies, Guillain-
Barre syndrome and limbic encephalitis. Treatment of HL usually arrests progression of, and 
occasionally improves the neurology (24). Paraneoplastic renal involvement usually manifests as 
glomerulonephritis, which can be of many types, such as minimal change, membranous or 
membranoproliferative glomerulonephritis (26). It may manifest clinically as nephrotic syndrome, 
and may precede the onset of HL by months to years (26).  
Skin manifestations of HL may be seen in 13-50% of patients (27-29). Most eruptions are non-
specific and can resemble conditions such as dermatomyositis and ichthyosis. Actual skin 
involvement by HL has been reported to in 0.5-7.5% of patients (27). Spread is usually retrograde 
from involved lymph nodes, and can be described as papules, infiltrations/plaques, 
nodules/tumours; ulcerative lesions and erythroderma. It may mimic infections like scrofuloderma 
and herpes zoster. Direct skin involvement by HL is usually a feature of advanced disease and may 
imply a poorer prognosis (27) . 
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Other abnormalities associated with HL include: hepatitis, cholangitis, vasculitis, 
hypercalcaemia, hypoglycaemia, coagulopathies and haemophagocytosis (30). 
 
1.4 Diagnosis of Hodgkin Lymphoma 
Hodgkin lymphoma (HL) requires histology for the identification of characteristic tumour cells 
(HRS or LP cells) within an appropriate reactive cellular background. Thus a complete excision 
biopsy of a lymph node is necessary so that the sparce tumour cells are not missed and the lymph 
node architecture can be appreciated (3). However, if the biopsy is from an extranodal site, the 
diagnosis may be challenging. 
There have been diagnostic errors in pathological classifications reported in some studies where 
NHL may be incorrectly diagnosed as HL in about 3-13% of cases. There has also been inter-
observer variation of up to 8% in the classification of HL by an expert panel (3). 
The use of cytology and fine needle aspiration (FNA) to diagnose HL has been shown to have a 
high false negative rate of 15-40% (3). Hence, FNA is not reliable for the diagnosis of HL. 
However, occasionally a tissue biopsy sample is not technically possible or may be invasive, and 
then the clinician may diagnose HL, based on the FNA. More recently, there are improvements in 
flow cytometry methods, specific for the detection of HRS cells, such as nine colour essays and 
gating methods to include HRS cells, as reported by Fromm, et al (31). NLPHL will still not be 
able to be detected in this manner (31). 
 
1.5 Staging and investigation of Hodgkin Lymphoma 
The Ann Arbor classification and the Cotswolds modification of the Ann Arbor staging for 
describing the stage of HL at the initial presentation has formed the basis upon which treatment 
15 
 
and prognosis is selected and has allowed comparison of results achieved by different investigators 
for almost 2 decades (32-35). This classification including the Cotswolds modification of the Ann 
Arbor staging system is still maintained as the standard classification for HL.Computed 
tomography scan (CT) is the usual technique for evaluating intrathoracic and infradiagramatic 
lymph nodes and importantly also the involvement of the spleen and liver with evidence of focal 
defects (35). Computed tomography scan (CT) also allows for the assessment of bulk disease, 
which is defined as mediastinal adenopathy/mass which occupies more than one third of the 
transthoracic diameter or a peripheral mass of more than or equal to 10cm in diameter. It also 
differentiates extranodal disease that is due to contiguous spread from distant extranodal 
involvement (35). 
A thorough history is necessary to determine the presence or absence of ‘B’ symptoms, 
performance status (PS) of the patient assessed using the Eastern Cooperative Oncology Group 
(ECOG) grading system (See Appendix C), pruritis and other presenting characteristics. 
A chest x-ray is also useful, but the mandatory test is the CT scan of the neck, thorax, abdomen 
and pelvis. A bone marrow trephine biopsy may indicate bone marrow involvement but opinions 
from different authors indicate  that where a PET-CT scan is performed, the bone marrow biopsy 
may not be necessary in early stages of HL (stage 1A or 2A) with no adverse risk factors as the 
probability of a positive bone marrow biopsy in these stages is very low (less than 15%) (33-36). 
With the increasing use of the PET scan with fluro-deoxyglucose  (FDG-PET), with CT as part of 
the initial staging to serve as a baseline for comparison to assess treatment response, one would 
ask if PET/CT scan has now replaced a  bone marrow biopsy (35). A meta-analysis by Pako et al. 
showed a sensitivity of 70% for FDG-PET, while the combination (i.e. PET/CT scan) showed a 
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sensitivity of 85.7% and indicated that only 1.1% of bone marrow involvement would be missed 
if bone marrow biopsy was omitted (33-36). 
A study by Schaefer et al. which included patients with HL and NHL showed that 42% of patients 
were upstaged with PET/CT compared to conventional staging when bone marrow was assessed. 
However, only in 14% of these (seven patients) did the stage change from limited stage to 
advanced disease, thus potentially warranting a change of therapy (37). Other helpful tests would 
be the Full blood count with a differential count, blood urea and electrolytes, liver function tests, 
serum calcium, uric acid, lactate dehydrogenase levels, T cell subsets, immunoglobulin levels and 
in the appropriate setting HIV serology. 
 
1.5.1 The role of PET/CT scanning in the staging of Hodgkin Lymphoma 
The use of FDG-PET in the initial staging of HL is gaining importance and favour in many parts 
of the world. PET/CT is more sensitive than conventional CT scanning; picking up 25-30% more 
disease than CT (38,39). However, this may upstage a patient and lead to overtreatment and 
additional related toxicity. With early stage disease on conventional CT scan only, cure rates are 
> 95%. Patients with advanced stage disease on conventional CT imaging will get more intensive 
systemic chemotherapy anyway. Thus the role of PET/CT in initial staging is particularly useful 
where treatment can be modified by doing an interim scan at 2- 4 months post treatment (38-41). 
 
1.6 Management of Hodgkin Lymphoma  
The current advanced and modern treatment of HL has resulted in very good outcomes and cure 
rates, making long term complications of chemo-radiotherapy a reality and an important 
consideration as part of disease management. However, there is a still a small proportion of patients 
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who have primary refractory disease (5-10%) or relapse after a complete response (10-30%), 
despite the overall high cure rates of 70-85% (38). 
Treatment of HL should aim at minimizing long term toxicities and achieving optimal cure rates 
and survival. 
 
1.6.1 Risk stratification of Hodgkin Lymphoma   
Based on the clinical scenario, staging, and degree of end-organ damage, patients with HL are 
categorised into the following three groups, according to the National Comprehensive Cancer 
Network (NCCN): 
- Early- stage favourable 
- Early - stage unfavourable  
- Advanced stage (8, 39) 
The National Comprehensive Cancer Network (NCCN) defines unfavourable factors for stage I-
II as follows: 
- Bulky mediastinal disease (mediastinal mass ratio [MMR; maximum width of 
mass/maximum intrathoracic diameter] greater than 0.33 or bulky disease greater than 10 
cm. 
- “ B symptoms ‘’ 
- Erythrocyte sedimentation rate (ESR) > 50mm/hr 
- More than two- three nodal sites of disease (8). 
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Table 2:   Unfavourable Risk Factors for stages I and II HL 
Risk Factor GSHG EORTC/LSA 
Age  - Plus or equal 50yrs 
Histology  - MC or LD 
ESR or B symptoms  < 50 mm/hr  if A or >30 if B <50mm/hr if A or >30 if B 
Mediastinal mass MMR > 0.33 MMR>0.35 
Number of nodal sites >2 >3 
Extranodal lesions Any - 
 
GSHG = German Hodgkin Lymphoma Study Group 
EORTC= European Organization for Research and Treatment of Cancer 
LD= Lymphocyte depletion 
MD= Mixed cellularity  
A= Absence of ‘B’ symptoms 
B= Presence of ‘B’ symptoms 
Patients with advanced disease are further risk stratified using the International Prognostic score 
(IPS), which includes the following risk factors (for scoring, each factor receives 1 point):  
- Albumin < 40g/l 
- Hemoglobin <10.5g/l 
- Male gender 
- Age ≥  45 years 
- Stage IV disease 
- Leucocytosis: white blood cell count (WBC) > 15×109/l). 
- Lymphopenia: lymphocyte count < 8% of WBC and or absolute lymphocyte count 
     < 0.6 ×109/l) (8, 39, 40). 
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Based on the IPS score, patients with advanced disease can be categorized as follows: 
- Good risk (IPS 0-1) 
- Fair risk    (IPS 2-3) 
- Poor risk  ( IPS 4-7) 
1.6.2 Management of classical Hodgkin lymphoma 
 Recommendations for primary treatment of classical Hodgkin lymphoma (cHL) vary by stage and 
risk stratification. Chemotherapy is followed by restaging with PET-CT (40-42). 
 
1.6.2.1 Early-stage Favorable Disease (stage 1a and stage 11a) 
Combined modality is the treatment of choice in patients with early-stage cHL. The National 
Comprehensive Cancer Network (NCCN) guidelines give the ABVD (doxorubicin 
[Adriamycin/bleomycin/vinblastine/dacarbazine) regimen a category 1 rating (i.e., the 
recommendation is based on high-level evidence and uniform NCCN consensus that the 
intervention is appropriate), but also list an 8-week Stanford V regimen (doxorubicin, vinblastine, 
mechlorethamine [or cyclophosphamide], etoposide, vincristine, bleomycin, and prednisone) as an 
alternative (8). 
For early stage, favorable disease 2-4 cycles of ABVD is administered. Two cycles are suggested 
in highly selected patients with very favorable disease characterized by the following.  
 No bulky disease  
 No extra lymphatic involvement  
 Fewer than three sites of disease  
 Erythrocyte sedimentation rate (ESR) <30 mm/hr., or <50 mm/hr. in patients without B 
symptoms  
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 The European Society for Medical Oncology (ESMO) guidelines recommend two to three 
cycles of ABVD followed by involved-field radiation therapy (IFRT). ESMO recommends 
against interim PET-guided treatment outside of clinical trials (8).  
 
1.6.2.2 Early-stage Unfavorable Disease 
The NCCN supports the following treatments for stage I-II unfavorable (non-bulky) cHL (8).  
 ABVD regimen for two cycles and additional ABVD cycles or ABVD with involved-field 
radiation therapy (ISRT), as warranted or  
 Stanford V regimen for three cycles (12 weeks) (the regimen includes ISRT) or  
 Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine and prednisone) regimen for two cycles with HRT.  
NCCN recommendations for treatment of early-stage unfavorable (bulky) disease are as follows: 
 ABVD for four cycles (category 1 recommendation) followed by HRT or  
 Stanford V regimen for three cycles (12 weeks) or  
 Escalated BEACOPP regimen for two cycles plus ABVD for two cycles plus ISRT  
The ESMO guidelines recommend four cycles of ABVD with IFRT. In younger patients (≤60 
years) a more intensive treatment can be considered, consisting of two cycles of escalated (8) 
BEACOPP followed by two cycles of ABVD with IFRT. 
 
1.6.2.3 Advanced-stage Disease (1B, 2B, 3, 4 and bulky disease) 
The NCCN supports the following treatments for stage III-IV, (non-bulky) cHL (8). 
 ABVD for six cycles or  
 In patients with an IPS <3, Stanford V regimen for three cycles (12 weeks) or  
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 In patients with an IPS ≥4, escalated BEACOPP regimen for six cycles  
 For stage III-IV (bulky) cHL, the NCCN recommendations are the same as above, with 
the addition of ISRT to original sites of bulky disease  
The ESMO guidelines recommend the following   (9, 41) 
 ABVD for six to eight cycles, followed by localized radiotherapy of residual lymphoma 
larger than 1.5 cm  
 Escalated BEACOPP for six cycles, followed by localized radiotherapy of residual 
lymphoma larger than 2.5 cm  
 
1.6.2.4 Refractory or Relapsed Disease 
Both the NCCN and ESMO guidelines recommend high-dose chemotherapy followed by 
autologous stem cell transplantation (ASCT) for refractory or relapsed disease. The selection of 
second-line chemotherapy is determined by comparison with the agents previously used. 
Brentuximab vedotin is recommended for patients who have a failure of autologous stem cell 
transplantation or failure of at least two prior multi-agent chemotherapy regimens (9, 41). 
 
1.6.3 Management of the elderly patient with HL 
With a second peak in the incidence of HL noted in patients over 60 years of age in developed 
countries, special consideration needs to be given to the management of HL in this sub-group. 
Elderly patients with HL tend to do worse than younger patients. Disease free survival (DFS) and 
Overall survival (OS) rates are about 20% lower than for young patients with HL. There are a few 
reasons for this. Older people have more co-morbid disease, such as cardiovascular and respiratory 
diseases. They tolerate cytotoxic chemotherapy less well, posing a challenge to administering 
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chemotherapy with a curative intent. Older patients present with more unfavorable risk factors as 
compared to young patients. It is hoped that new agents such as monoclonal antibodies, which are 
better tolerated, will provide a new ray of hope for the optimal management of the elderly patient 
with HL (42). 
 
1.6.4 PET and CT scans after treatment 
Position emission tomography/ Computerized tomography scans (PET/CT) (are very useful in 
assessing residual masses at the end of chemotherapy. Normally, patients with negative scans after 
treatment are assumed to be in complete remission (CR). Therefore, treatment can be stopped in 
this type of patient in CR, as more chemotherapy /radiotherapy has no benefit. However, about 
25% of patients with residual disease / masses at the end of chemotherapy will have positive PET 
scans and they are treated with radiotherapy if localized or chemotherapy if generalized, followed 
by autologous stem cell transplantation in chemosensitive patients. False positive PET scans may 
occur in some patients. Results of current trials addressing this issue will hopefully clarify further 
management (32). 
 
1.6.5 The role of stem cell transplantation in the management of Hodgkin lymphoma  
High dose chemotherapy (HDCT) and Autologous Stem cell transplant (ASCT) is the standard 
treatment for patients in first relapse, although patients with localized disease at relapse may still 
benefit from radiotherapy. For patients with primary refractory disease, the outcome is not as 
promising after HDCT and ASCT as compared to patients with relapsed disease. However, these 
patients with primary refractory disease still have a 20-30% chance of cure with ASCT,  after 
failing first and second line chemotherapy (43). 
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Position emission tomography/ Computerized tomography scans (PET/CT) do play a significant 
role prior to highly toxic therapy in patients considered for transplant. PET/CT scan can be used 
to assess the response to second line chemotherapy prior to HDCT and ASCT. A positive PET/CT 
scan before transplant is usually associated with higher relapse rates and poorer outcomes post 
ASCT. However, not all patients with a positive PET/CT  scan will relapse post-transplant (7-56% 
of patients in studies do not relapse), and  thus a positive scan should not be the reason for denying 
a patient HDCT and ASCT, which may be their only chance of cure (9). 
For patients who relapse after ASCT, the possibility of an allogeneic stem cell transplant (allo -
SCT) does exist. Myeloablative regimens are highly toxic and result in increased morbidity and 
high transplant-related mortality of 20%. According to transplant registry data, allo-SCT has not 
been superior to ASCT in terms of PFS and DFS, despite lower relapse rates (43). The increasing 
practice of reduced intensity conditioning (RIC) allo-SCT in the United Kingdom has been 
promising. When RIC allo-SCT was compared to myeloablative allo-SCT, RIC regimens were 
associated with lower transplant related mortality. The increased incidence of chronic graft versus 
host disease (GVHD) in RIC allo-SCT resulted in lower relapse rates, and was associated with an 
improved PFS and OS (43). The possibility of graft-versus Hodgkin effect in patients treated with 
RIC regimens also provides potential for donor lymphocyte infusions as a therapeutic option. The 
use of monoclonal antibodies and histone deacetylase inhibitors is being tested in clinical trials to 
assess their utility as maintenance therapy post ASCT to decrease relapse rates. If successful, these 
agents could potentially be used in allo-SCT as well (43). 
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1.6.6 New therapies in the management of Hodgkin Lymphoma 
The development of novel, targeted therapies offers some hope in the management of HL in 
patients who are resistant to chemotherapy and who do not tolerate the toxicity of conventional 
regimens (44, 45). 
 
1.6.6.1 Monoclonal Antibodies 
 Monoclonal antibodies to CD30 were previously disappointing due to low response rates and high 
toxicity. Current preparations are much more promising and better tolerated. Brentuximab vedotin 
is an antibody-drug conjugate, comprising of anti-CD30 chimeric monoclonal antibody, 
conjugated to an anti-tubulin, auristatin. In a phase II trial of 102 patients who failed ASCT, the 
overall response rate was 75% with 34% of patients achieving a CR. The response was durable, 
with a median duration of 47 weeks (46-47). 
 
1.6.6.2 Rituximab  
Rituximab is a chimeric monoclonal antibody to CD20 and has shown favorable responses in 
patients with relapsed and refractory NLPHL. Patients with cHL who had multiple relapses may 
also respond to rituximab. Patients with NLPHL who are treated with rituximab may relapse with 
a CD20 negative T cell-rich B cell NHL (48). 
 
1.6.6.3 Histone deacetylase (HDAC) inhibitors 
In a study in which Panobinostat was used, an overall response rate of 27% was seen in 129 patients 
who failed ASCT and the median Progression free survival (PFS) was 5.7 months (45). 
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1.6.6.4 Mammalian target of rapamycin (mTOR) inhibitors 
Everolimus is an (mTOR) inhibitor. An overall response rate of 47% was seen in patients who had 
relapsed disease. Eight patients had a partial remission (PR), while one patient had a complete 
remission (CR), with four of these patients being free from progression at 12 months (49, 50). 
 
1.6.7 Side effects of Hodgkin lymphoma treatment 
Hodgkin lymphoma (HL) treatment toxicity is similar to other cancer treatments. This includes 
myelosuppression and other related side effects like neurotoxicity and direct organ toxicities from 
either chemotherapy and or radiotherapy. 
Kaplan developed a concept of extended field radiotherapy (EFRT) in 1962 for the treatment of 
HL. This resulted in a five year survival improvement  to 70% in patients with localized disease 
(49-51). In the 1970’s, MOPP chemotherapy (mechlorethamine, oncovin, procarbazine, and 
prednisone) was used. In the 1980’s,  ABVD was introduced in patients that were resistant and 
refractory to MOPP, while stem cell transplantation remained another option (50). 
Since most of the HL patients are young, improvements in therapy increased the cure rate to > 70-
85% with early favorable disease. With higher cure rates and increased longevity, the late effects 
of treatment have become more apparent. These late side effects vary between individuals in 
relation to the time period post treatment, and modality of treatment received by the patients. Most 
importantly, patients must be informed of these side effects prior to treatment so that adequate 
follow up and screening post therapy is facilitated. These late effects include: 
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1.6.7.1 Second malignancies 
Second malignancies are responsible for most of the morbidity and mortality of HL survivors. 
Most of these malignancies are caused by radiotherapy (RT). RT has a cumulative incidence of 
development of a second malignancy of 11% at 20 years and 26% at 30 years respectively (52,53). 
Solid organ tumors like lung cancer, non-melanoma skin cancer, breast cancer and colo-rectal 
cancer are the most common second malignancies. Less commonly, sarcomas and NHL may 
occur. Adolescent females are at greater risk for the development of breast cancer, especially those 
who have received mantle radiotherapy at doses greater than 30Gy (54).  The above mentioned 
cancers have a median time of 14.3 years after treatment and the risk keeps rising with time (55). 
MOPP (mechlorethamine, oncovin, procarbazine, and prednisone) and BEACOPP (bleomycin, 
etoposide, Adriamycin, cyclophosphamide, oncovin, procarbazine and prednisone) are 
combination therapies that contain alkylating agents and may be responsible for myelodysplasia 
and acute leukemia. These complications present at 10 years post therapy with a median latency 
of three years (54-55).  
With the introduction of involved field radiotherapy (IFRT) and involved node radiotherapy 
(INRT), there has been a substantial reduction of radiation volumes to the organs like the lungs, 
breast tissue and the heart compared to patients who previously received mantle RT. The new 
standard of care for early stage disease is 20Gy of IFRT. This may result in reduced doses of 
radiation and consequently 80% of reduction of radiation dose to breast tissue compared with the 
previous mantle RT (53). Therefore, in patients who have been exposed to more than 30Gy to the 
abdomen, pelvis or spine, colo-rectal screening is very important and should start at the age of 35 
or 15 years post treatment (54). Monthly breast examination and annual mammography are 
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recommended for patients at risk of breast cancer from the age of 25 years and eight years post 
therapy (54). 
 
1.6.7.2 Thyroid disease 
Radiotherapy (RT) damages the thyroid vasculature, and up to one third of patients may develop 
thyroid abnormalities, with hypothyroidism being the most common, although it may be 
subclinical. Other reported thyroid diseases are Grave’s disease, multinodular goiter, thyroiditis, 
adenoma and carcinoma. Subclinical hypothyroidism must be treated with eltroxin in order to 
avoid over- stimulation of a gland that is at risk of malignancy. Patients should have annual thyroid 
function tests done and a palpable nodule needs to be investigated (52-55). 
 
1.6.7.3 Cardiovascular disease 
Hodgkin lymphoma (HL) associated cardiovascular disease may be due to the accelerated 
coronary effects normally caused by mediastinal RT, at doses of more than 35Gy and or 
anthracycline use with a cumulative risk of 5-10% at 15 years, 16% at 20 years and 34% at 30 
years respectively (56, 57). Though the use of IFRT has reduced the risk of cardiovascular disease, 
it still carries a risk because it involves the superior one third of the heart and the coronary arteries 
are still in the radiation field.  
Mantle RT causes atherosclerosis and left ventricular (LV) dysfunction. However, LV dysfunction 
with congestive cardiac failure (CCF) can be caused by anthracycline therapy where doses above 
the toxic limit have been administered (> 550mg/m2 of Adriamycin) and this is normally 1 year 
after treatment. Other cardiovascular effects include subclinical cardiomyopathy which usually 
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occurs in patients receiving less than toxic doses with a median follow up of eight years after 
therapy (56). 
Mediastinal RT may cause cardiac valve dysfunction with a risk of 5% in 20 years. Accelerated 
atherosclerosis may occur in the carotid and subclavian arteries post RT, leading to an increased 
risk of stroke and transient ischemic attacks. 
 
Risk factors like smoking and existing cardiovascular diseases have to be addressed prior to 
therapy and management initiated for existing cardiovascular diseases.  
Therefore, screening is vital before and after treatment and includes an ECG, Echo sonography 
(echocardiography) and careful examination for cardiovascular abnormalities. 
There is evidence that anti-failure treatment such as the angiotensin converting enzyme inhibitors 
and beta blockers like carvedilol may play an important role in asymptomatic left ventricular 
dysfunction, thus preventing progression to/of cardiomyopathy (58). 
 
1.6.7.4 Infertility  
The risk of developing premature ovarian failure and azoospermia is a major concern in long-term 
survivors treated for Hodgkin lymphoma. Alkylating agents such as cyclophosphamide and 
procarbazine cause prolonged azoospermia in 90–100% of men and premature ovarian failure in 
5– 25% of women under the age of 30. The risk of infertility increases with the cumulative dose 
of alkylating agents and the risk is high after salvage therapy, including conditioning 
chemotherapy prior to autologous or allogeneic transplantation (57,58). The doxorubicin-
bleomycin-vinblastine-dacarbazine regimen is associated with a lower risk of gonadal damage and 
the rate of infertility is less than 10%. The risk of premature ovarian failure is limited after the 
doxorubicin-bleomycin-vinblastine-dacarbazine regimen. However, age is an important factor; 
29 
 
women over 30 years of age are at  much higher risk of ovarian failure (59). Semen 
cryopreservation should be routinely offered, especially before initial treatment with bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone or salvage 
therapy with high-dose chemotherapy and autologous transplantation. 
Pelvic RT and total body radiation is associated with gonadal damage. This results in ovarian 
failure leading to premature menopause. Therefore, screening with a thorough physical 
examination is very important, as is patient education and information on infertility, prior to 
therapy (59-61). 
 
1.6.7.5 Other associated effects of HL treatment 
Mediastinal RT and or use of bleomycin may cause pulmonary effects (such as pulmonary fibrosis, 
acute respiratory distress syndrome and interstitial pneumonitis). Pulmonary effects have also been 
reported in elderly patients on bleomycin, even with lower doses (62). 
Other associated effects include fatigue, psychosocial problems such as anxiety, depression and 
post- traumatic stress disorder. 
An increased infection risk exists in patients who have had prior splenectomy or splenic irradiation. 
These patients should receive the influenza vaccine yearly and patients who have had a 
splenectomy must receive additionally, booster pneumococcal and haemophilus influenza 
vaccination at appropriate time intervals.  
 
1.7 Human immunodeficiency virus (HIV) and Hodgkin lymphoma 
The above two mentioned pathologies present with a peak incidence in the 4th decade (14). With 
the current introduction of anti-retroviral drugs, HIV sero-positive patients have an improved 
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survival. HIV associated HL (HIV-HL) differs somewhat from HL in HIV negative patients in 
terms of incidence, pathology, clinical features, response to treatment and prognosis. 
 
1.7.1 Epidemiology of HIV-HL 
 
1.7.1.1 Incidence and epidemiology  
Hodgkin lymphoma (HL) is a non AIDS defining cancer with an increased incidence in HIV 
positive patients compared to HIV negative patients. The relative risk is 10-20 fold increased with 
HIV seropositivity (14).  
While AIDS- defining cancers like Non-Hodgkin’s Lymphoma and Kaposi Sarcoma are 
decreasing in incidence with the advent of highly active anti-retroviral therapy (HAART), the 
incidence of non-AIDS defining cancers like HL is on the rise (63). 
EBV is associated in almost all cases of HIV-HL due to the impaired immunity in HIV seropositive 
patients. The EBV latent membrane protein 1 (LMP-1) is found in tissue samples of HIV-HL. 
LMP1 is responsible for the constitutive NFĸB expression that results in activation of signalling 
pathways for cell growth and decreased apoptosis (17).  
 
1.7.1.2 Clinical Features of HIV-HL 
Patients with HIV-HL commonly present with ‘B’ symptoms, advanced stage disease and more 
aggressive disease. Involvement of the bone marrow, liver and spleen are more common than in 
HIV seronegative HL (14). 
 A study from the Italian cooperative group on AIDS and Tumours (GICAT) showed that patients 
who were on antiretroviral drugs at the time of HL diagnosis, had B symptoms, were older, had a 
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higher  hemoglobin level and had higher neutrophil counts indicating that  antiretroviral drug  
exposure prior to the diagnosis of HL may somehow modify the clinical picture (64). 
 
1.7.1.3 Pathology of HIV-HL 
Patients Pre- HAART with HIV-HL were commonly of the mixed cellularity and lymphocyte 
depleted subtypes of classical HL. In the post- HAART era, this trend has continued but 
additionally with the nodular sclerosis subtype. However, mixed cellularity is still the most 
common histological subtype in HIV-HL (14, 64). 
 
 
1.7.1.4 Management of HIV-HL 
Management of HIV-HL is subdivided into supportive and specific treatment. 
Supportive measures: This involves general supportive measures and antiretroviral therapy 
(analgesics, blood products, antibiotics, allopurinol, growth factors etc.). 
Specific treatment:  This includes combination chemotherapy regimens such as ABVD, EBVP, 
MOPP/ABVD hybrid and Stanford V. Remission rates and overall survival are generally lower 
than in patients with HIV seronegativity (14). 
 
1.7.1.4.1 The benefits of antiretroviral drugs 
Patients on antiretroviral therapy have shown less morbidity and higher remission rates associated 
with improved survival compared to patients not on antiretroviral therapy. Antiretroviral therapy 
allows for the delivery of standard doses of chemotherapy on time and the option of salvage 
therapy by autologous stem cell transplantation in relapsed patients with HIV-HL (63,64). 
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1.8 Tuberculosis and Hodgkin Lymphoma 
Tuberculosis and HL have similar clinical features such as the presence of constitutional 
symptoms, lymphadenopathy, bone marrow infiltration and splenomegaly. Both conditions can 
coexist in the same patient. Lymph node and bone marrow samples may show evidence of both. 
Therefore, pathologists need to look carefully for HRS cells with characteristic staining properties 
and perform stains for Acid-fast bacilli, cultures of mycobacterium TB and in difficult cases, 
polymerase chain reaction (PCR) to identify TB organisms (65-67). 
Tuberculosis in association with HL is common. A study by Kaplan et al. of 201 patients showed 
an increased incidence of TB in HL. The increased association is due to impaired cellular immunity 
that predisposes patients with HL to infections (65). Depressed immunity can also be due to 
chemotherapy, and may facilitate a reactivation of dormant TB bacilli and dissemination of 
infection. It is therefore imperative that clinicians and pathologists be aware of the close 
association between TB and HL, especially in areas where TB is endemic, thus ensuring prompt 
diagnosis of both conditions and timeous institution of appropriate therapy. More work needs to 
be done regarding interpretation of PET scans in patients with TB and malignancy as false positive 
results may occur in the presence of infections such as TB (66,67). 
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2.0 CHAPTER TWO: PATIENTS AND METHODS. 
 
2.1 Study design 
This is a retrospective review of all patients with a confirmed histological diagnosis of Hodgkin 
lymphoma seen at the adult Clinical Hematology Unit, Department of Medicine, CHBAH, from 
January 2005 to December 2012. 
 
 2.2 Study Population 
Adult patients with a confirmed diagnosis of HL were admitted to the study with a cut-off age of 
14 years and above as per the hospital admission criteria. Patients without histological 
confirmation of HL were excluded from the study.  
 
2.3 Methods and Procedures  
The data were collected using the data collection sheet as shown in Appendix A. Patients were 
identified using a study number with the name and hospital number being kept on a separate 
list/sheet. Demographic, clinical, laboratory – including histology, radiological and treatment 
parameters were recorded on all patients. Response to treatment, and prognostic factors 
influencing survival and outcome, were also documented. Data was collected on a data collection 
sheet, after each of the patient files were reviewed. Outcomes to be used for the Kaplan Meier 
curves were defined as patients who died or were lost to follow up. For the survival analysis, time 
to event (death/lost to follow up) was recorded using the data collection sheet.  
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2.4 Data entry and statistical analysis 
Information from the patient’s files was captured in a Microsoft Excel spread sheet database. The 
data was analysed by a Statistician. Frequencies of categorical variables were compared using a 
chi square test. Continuous variables were reported as mean ± standard deviation and differences 
between groups were compared using a student t-test or non-parametric test (Mann-Whitney) if 
not normally distributed. 
 Kaplan-Meier curves were used to determine whether prognostic variables were affecting survival 
and whether co-variates affected survival. The data was censored for patients lost to follow up. 
Kaplan Meier curves were used over cox regression as the main aim was to describe the survival 
rates of patients based on their prognostic variables. Age distribution between HIV positive and 
negative patients was compared using the non-parametric Wilcoxon rank-sum test. Frequencies of 
categorical variables such as gender, performance status, site of lymphadenopathy and B 
symptoms were compared using the Pearson chi square test. All statistical analysis was computed 
to a significance level of 5% (i.e. p<0.05). 
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3.0 CHAPTER THREE: RESULTS 
                                                 
A total of 167 patients with a confirmed diagnosis of HL were seen during the period 01/01/2005 
to 31/12/2012. Seventeen patients were excluded due to incomplete or inadequate information. 
The remaining 150 patients were evaluable and formed the current study population. 
 
3.2 Descriptive statistics:  Frequencies 
Table 1: Gender distribution 
 Frequency Percent Valid Percent Cumulative Percent 
 Female 66 44.0 44.0 44.0 
Male 84 56.0 56.0 100.0 
Total 150 100.0 100.0  
 
 
 
Figure 1: Gender distribution 
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Table 3 and figure 2 show the percentage breakdown of the distribution of the 150 patients who 
participated in the survey according to gender. There were 84 males (56%) and 66 females (44%). 
The male to female ratio was 1.27:1. 
 
Table 2: Current occupation 
 
 Frequency Percentage Valid 
Percentage 
Cumulative 
Percentage 
Unemployed  
Factory workers 
Scholars 
Own Business 
Security guard 
Merchandiser 
Hospitality industry 
Prisoner 
Pensioner 
Not documented 
Finance  industry 
Priest 
Motor mechanic  
Total 
71 
22 
16 
8 
6 
5 
5 
4 
4 
4 
3 
1 
1 
150 
47.3 
14.7 
10.7 
5.3 
4.0 
3.3 
3.3 
2.7 
2.7 
2.7 
2.0 
0.7 
0.7 
100 
47.3 
14.7 
10.7 
5.3 
4.0 
3.3 
3.3 
2.7 
2.7 
2.7 
2.0 
0.7 
0.7 
100 
 
47.3 
62.0 
72.7 
78.0 
82.0 
85.3 
88.6 
91.3 
94.0 
96.7 
98.7 
99.3 
100.0 
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Figure 2: Current occupation 
 
Table 4 and figure 2 above show the breakdown of the distribution of the 150 patients who 
participated in the survey according to current occupation. A significant number of patients were 
unemployed at the time of diagnosis of the Hodgkin lymphoma. The three most common 
occupations were: Factory workers 14.7%, Scholars 10.7% and Business owners (own business) 
5.3%. 
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Table 3: Age distribution 
 
 Frequency Percentage Valid 
Percentage 
Cum 
(%) 
10-20 27 18.0 18.0 18.0 
21-30 43 28.7 28.7 46.7 
31-40 47 31.3 31.3 78.0 
> 40 33 22.0 22.0 100.0 
Total 150 100.0 100.0  
 
 
 
Figure 3: Age distribution 
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The above table and figure show the breakdown of the distribution of the 150 patients who were 
studied in the survey according to age. The peak frequency was in the fourth decade of life 
(31.33%). Mean, median and range are shown below in table 3.4 as being 36 years, 37 years and 
15-78 years respectively. 
 
Table 4: Descriptive age analysis 
 
 
Statistic 
 
Std. Error 
 
AGE Mean 36.99 1.025 
95% Confidence Interval for  Lower Bound 34.97  
Upper Bound 39.02  
5% Trimmed Mean 36.38  
Median 37.00  
Variance 155.59  
Std. Deviation 12.47  
Minimum 15  
Maximum 78  
Range 15-78  
Interquartile Range 14  
Skewness .653 .199 
Kurtosis .975 .396 
 
The table above gives the descriptive analysis of age as a continuous variable. The mean age of 
the patients was 36.99±12.47 years. The age range for the study participants was 15-78 years. 
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Table 5: Ethnic group distribution 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
 
Black 
Coloured 
Asian 
White 
Total 
 
140 
6 
3 
1 
150 
 
93.3 
4.0 
2.0 
0.7 
100 
 
93.3 
4.0 
2.0 
0.7 
100 
 
 
 
93.3 
97.3 
99.3 
100 
100 
 
 
 
 
 
Figure 4: Ethnic group distribution 
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Table 7 and figure 4 show the breakdown of the distribution of the 150 patients who participated 
in the survey according to ethnic group. The vast majority of the patients were black (non-
Caucasians), accounting for 93.3% of the total 
 
Table 6: Performance status 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
0 26 17.3 17.3 17.3 
1 24 16.0 16.0 33.3 
2 22 14.7 14.7 48.0 
3 48 32.0 32.0 80.0 
4 30 20.0 20.0 100.0 
Total 150 100.0 100.0  
 
 
Figure 5: Performance status                                                                       
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Performance status (PS) was assessed using the Eastern Cooperative Oncology Group (ECOG) 
grading system (See Appendix C). Table 8 and figure 5 show that 48% of the patients had a 
performance status of ≤ 2, while 52% had a performance status of 3 or 4. 
 
Table 7: ‘B’ symptoms 
 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 No 38 25.3 25.3 25.3 
Yes 112 74.7 74.7 100.0 
Total 150 100.0 100.0  
 
‘B symptoms’ include fever, night sweats and weight loss. One hundred and twelve patients 
(74.7%) had ‘B’ symptoms at presentation, while 41.3% of the patients did not present with ‘B’ 
symptoms. 
 
Table 8: HIV status 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 Negative 60 40.0 40.0 40.0 
Positive 90 60.0 60.0 100.0 
Total 150 100.0 100.0  
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Figure 6: HIV status 
 
The above diagram shows the distribution of the 150 patients with regard to HIV status. HIV 
positive patients accounted for 60.0% in comparison to 40% who were HIV negative. 
 
Table 9: Comorbid disease excluding HIV and TB 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 No 102 68.0 68.0 68.0 
Yes 48 32.0 32.0 100.0 
Total 150 100.0 100.0  
 
Comorbid diseases included hypertension, diabetes, stroke and connective tissue diseases, such as 
SLE, and RA. As shown above, 32.0% had an underlying comorbid disease. 
 
 
Negative
40%
Positive
60%
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Table 10: Lymphadenopathy 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 No 11 7.3 7.3 7.3 
Yes 139 92.7 92.7 100.0 
Total 150 100.0 100.0  
 
The above table shows the breakdown of the distribution of the 150 patients who participated in 
the survey. Lymphadenopathy was present in 92.7% of the patients at presentation. 
 
Table 11: Site of lymphadenopathy 
 
 
Frequency 
 
Percent 
 
Valid Percent 
 
Cumulative 
Percent 
 Cervical only  30 21.5 21.5 21.5 
Non-cervical 24 17.3 17.3 38.8 
Cervical and Non 
cervical 
85 61.2 61.2 100 
Total 139 100 100  
 
The above table shows the site of lymphadenopathy at presentation. Cervical lymphadenopathy 
was present in 82.7% of the patients, while non-cervical sites only were involved 17.3% of the 
patients. 
 
Table 12: Tuberculosis in association with HL 
 
 Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 No 91 60.7 60.7 60.7 
Yes 59 39.3 39.3 100.0 
Total 150 100.0 100.0  
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The above table shows the breakdown of the distribution of the 150 patients in regard to the 
association of Tuberculosis.  Fifty-nine patients (39.3%) had an association of TB, compared to 
60.7% with no association of TB. 
 
Table 13: Diagnosis of Tuberculosis 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 Prior to lymphoma diagnosis 47 79.7 79.9 79.7 
During lymphoma treatment  12 20.3 20.3 100 
                                Total 59 100.0 100.0  
 
The above table shows the distribution of the 150 patients who had an association of Tuberculosis 
in relation to the time of the diagnosis of HL. Forty-seven patients (79.7%) had a diagnosis of TB 
made prior to lymphoma diagnosis whereas 20.3% were diagnosed after the lymphoma diagnosis 
while on treatment for lymphoma.  
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Table 14: Hepatomegaly and splenomegaly in HL 
 
 
 
 
Both the liver and spleen were involved in 43.5% patients. Hepatomegaly only was present in 
46.4% while splenomegaly only was evident in 10.1% of the patients. 
 
Table 15: Bone marrow involvement 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 No 122 81.3 81.3 81.3 
Yes 28 18.7 18.7 100.0 
Total 150 100.0 100.0  
 
Bone marrow infiltration was present in 18.7% of the patients at presentation.  
 
 
 
 
 
 
 
 Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
Liver only 32 46.4 46.4 46.4 
Spleen only 07 10.1 10.1 56.5 
Both Liver 
and Spleen  
30 43.5 43.5 100 
Total 69 100 100  
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Table 16: Ann Arbor stage 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 1a 5 3.3 3.3 3.3 
1b 6 4.0 4.0 7.3 
2a 12 8.0 8.0 15.3 
2b 16 10.7 10.7 26.0 
3a 13 8.7 8.7 34.7 
3b 18 12.0 12.0 46.7 
4a 8 5.3 5.3 52.0 
4b 72 48.0 48.0 100.0 
Total 150 100.0 100.0  
 
 
 
Figure 7: Ann Arbor stage 
 
Table 18 and figure 7 shows the Ann Arbor stage of the patients at diagnosis. Over half of the 
patients had stage 4 disease (53.3%), while 20.7% of the patients presented with stage 3 disease. 
Stage 1 and 2 disease accounted for 7.3% and 18.7% of the patients respectively. ‘B’ symptoms 
were present in 74.7% of the patients. 
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Table 17: Chemotherapy 
 
 
Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 No 19 12.7 12.7 12.7 
Yes 131 87.3 87.3 100.0 
Total 150 100.0 100.0  
 
Of the 150 patients in the study, 87.3% received chemotherapy and 12.7% did not receive 
chemotherapy. All the patients who received chemotherapy received initial combination 
chemotherapy, most commonly with ABVD (Adriamycin, bleomycin, vinblastine, decarbazine) 
and prednisone.  
 
Table 20: Treatment response after first line chemotherapy 
 
Total number of patients who 
received > 2 cycles of 
chemotherapy 
Achieved PR Achieved 
CR 
Defaulted/lost 
to follow 
up/unknown 
Died 
 
 
109 35 10 29 35 
 
 
Table 21: Treatment response after ASCT 
 
Total number of patients who 
received ASCT 
Alive Relapsed Defaulted/lost 
to follow up 
Died 
 
10 04 03 02 01 
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Table 19 shows that 87.3% received chemotherapy and 12.7% died prior to receiving 
chemotherapy. The median number of cycles received was 7.5. Of the patients that received initial 
chemotherapy, 22 patients received less than 2 cycles of chemotherapy, 48 patients received 2 or 
more but less than 8 cycles of chemotherapy, and 61 patients received 8 or more cycles of 
chemotherapy. 
 
Table 18: Disease outcome 
 
 Frequency 
 
Percent 
 
Valid 
Percent 
Cumulative 
Percent 
 Alive 48 32 32 32 
Died 44 29.3 29.3 61.3 
Defaulted 58 38.7 38.7 100.0 
Total 150 100.0 100.0  
 
The above table shows the breakdown of the 150 patients with regard to outcome. Currently 48 
patients (32%) are alive, 44 patients (29.3%), have died and 58 patients (38.7%) are lost to follow 
up /defaulted/could not be traced.  
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Table 19: Comparison of HIV negative with HIV positive patients 
 
Characteristics 
 
HIV positive 
N=90 
HIV negative  
N=60 
p-value 
 
 N (%) N (%)  
Age    
Mean (years)  37.8 35.8 0.0569 
Age group    
<40 years 62 (70.45) 37 (61.67) 0.2647 
>40 years  26 (29.55) 23 (38.33) 0.2647 
Gender     
female  38 (42.22) 28 (46.67) 0.2849 
male  52 (57.78) 32 (53.33) 0.2849 
B symptoms    
present 70 (77.78) 42 (70.00) 0.3103 
absent  20 (22.22) 18 (30.00) 0.3103 
Histological subtypes    
  Mixed cellularity   36 (40.00) 13 (21.67) 0.0190 
  Nodular sclerosis   21 (23.33) 28 (46.67) 0.0028 
  Lymphocyte rich    2 (2.22) 2 (3.33) 0.6790 
  Lymphocyte depleted  6 (6.67) 1 (1.67) 0.1549 
  Unclassified 25 (27.78) 16 (26.67) 0.8811 
Bone marrow involvement     
disease present 24 (26.67) 4 (6.67) 0.0007 
disease absent  66 (73.33) 56 (93.33) 0.0007 
True extra nodal disease     
yes  4 (4.44) 1 (1.67) 0.3533 
no  86 (95.56) 59 (98.33) 0.3533 
Association with TB     
yes  44 (48.89) 14 (23.33) 0.0016 
no  46 (51.11) 46 (23.33) 0.0016 
Liver involvement only  23 (25.36) 8 (13.33) 0.0701 
Spleen involvement only  4 (4.44) 2 (3.33) 0.7337 
Both liver and spleen involvement  20 (33.3) 10 (16.7) 0.3708 
Stage 3 and 4 disease  60 (66.67) 34 (56.67) 0.2148 
Bulk disease     
yes  9 (10.00) 6 (10.00) 1.0000 
no  81 (90.00) 54 (90.00) 1.0000 
Performance status    
0 15 (16.67) 11 (18.33) 0.7916 
1 12 (13.33) 12 (20.00) 0.2752 
2 10 (11.11) 12 (20.00) 0.1317 
3 31 (34.44) 17 (28.33) 0.4318 
4 22 (24.44) 8 (13.33) 0.0956 
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The above table shows a comparison of the demographic and clinical characteristics between HIV 
seropositive and HIV seronegative patients. There were more HIV positive patients (60%) than 
HIV negative patients (40%). A review of the different parameters indicate only a statistically 
significant difference in relation to histology (p=0.019), TB association (p=0.002), and bone 
marrow involvement by disease (p=0.0007), between HIV seropositive and HIV seronegative 
patients. However, as per the protocol questionnaire no data was collected regarding CD4 count 
and viral load for HIV positive patients and patients who were on ARVs. 
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Table 20: Laboratory results 
 
Number of 
Patients 
Blood Parameters Mean Range Percentage 
Females = 66 
Males  = 84 
Hemoglobin (g/dl)    09 1.8-16.5 < 12 in females =36/66 (54.5%) 
< 13 in males = 48/ 84 (57.1%) 
< 10.5 = 88/150 (58.7%) 
 White cell count  
(×109/l) 
6.0 1.0-45.0 < 4 in 28/150 (18.7%) 
>10 in 08/150 (5.3%) 
>15 in 04/150 (2.7%) 
 Platelets (×109/l ) 155 10-725 < 100 in 12/150 (8%) 
> 450 in 36/150 (24%) 
 Albumin (g/l) 35 15-48 < 40 in 60/150 (40%) 
< 35 in 34/150 (22.7%) 
< 30 in 26/150 (17.3%) 
 Neutrophil count 
(×109/l) 
1.8 0.4-7.5 <4 in 6/150 (4%) 
>7.5 in 3/150 (2%) 
 Lymphocyte count 
(×109/l) 
1.43 0.75 <1 in 06/150 (4%) 
>4 in 24/150 (16%) 
 Eosinophil count  
(×109/l) 
0.01 0-2.50 <0.4 in 8/150 (5.3%) 
 Lactate 
dehydrogenase (U/L) 
455 225-3845  >200 in 60/150 (40%) 
>1000 in 11/150 (7.3%) 
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The above table shows a summary of the relevant blood results. More than 50% of the patients had 
anaemia. Thrombocytopenia was noted in 8% of the patients, while thrombocytosis was evident 
in 24% of the patients. Leucopaenia and leucocytosis were uncommon, accounting for 4% and 2% 
of the patients respectively. Hypoalbuminaemia and an elevated LDH were both present in 40% 
of the patients, respectively.  
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Table 21: Distribution of histological subtypes 
 
Histological subtype Frequency Percentage Valid 
percentage 
Cumulative 
percentage 
Mixed cellularity 49 32.7 32.7 32.7 
Nodular sclerosis 49 32.7 32.7 65.4 
Lymphocyte  rich 4 2.7 2.7 68.1 
Lymphocyte depleted 7 4.6 4.6 72.7 
Un-classified 41 27.3 27.3 100 
Total 150                 100 100  
 
 
 
Figure 8: Distribution of histological subtypes 
 
The above diagrams show the breakdown of the distribution of the 150 patients who participated 
in the survey according to the distribution of histological classification of subtypes. Both Mixed 
55 
 
cellularity and Nodular sclerosis were the predominant subtypes seen, each accounting for 49 
patients (32.7%) respectively.  
 
Table 26: True-extranodal disease in HIV seropositive and HIV seronegative patients 
 
Site of disease Number of patients HIV Positive HIV Negative 
Pleural effusion 03 01 02 
Para spinal mass 02 02 00 
Bone lytic lesions 02 02 00 
Lung nodules 01 00 01 
Breast mass 01 01 00 
Tonsillar mass 01 01 00 
GIT involvement 01 00 01 
TOTAL 11 01 01 
  
 
3.3 Kaplan- Meier survival curves 
Kaplan-Meier survival curves for the entire study population, age group (age <40 years versus age 
>40 years), early disease versus advanced disease, HIV seropositive versus HIV seronegative 
status, presence versus absence of ‘B’ symptoms, histological subtypes and comorbid disease 
versus no-comorbid disease are all indicated in the figures below.  
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Figure 3: Kaplan Meier survival curve – overall survival 
 
The curve for the overall survival of Hodgkin lymphoma patients shows that the probability of 
survival gradually declines with time. The median overall survival is 21.5 months. 
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Figure 4: Kaplan Meier survival curve by age group (<40 years vs >40 years) 
 
Figure 10 shows the Kaplan Meier survival curve by patient age group. The figure shows that 
patients who were > 40 years had a higher probability of survival. This is contrary to older age 
being an adverse prognostic factor and may be explained by the fact that there were fewer patients 
that were older than 40 years in this study, and less patients who were HIV seropositive over the 
age of 40 years. 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
c
u
m
u
la
ti
v
e
 s
u
rv
iv
a
l
0 10 20 30 40
analysis time (months)
<40 >40
Kaplan-Meier curve by age group
58 
 
 
Figure 5: Kaplan Meier survival curve by disease stage (early vs advanced) 
 
Figure 11 shows the Kaplan Meier survival curve by disease stage. Early stage appears to have a 
better survival. However, with overlap between the two curves, there was no difference in the 
survival probability of patients with early disease versus those with advanced disease.  
 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
c
u
m
u
la
ti
v
e
 s
u
rv
iv
a
l
0 10 20 30 40
analysis time (months)
advanced disease sta early disease stage
Kaplan-Meier curve by disease stage
59 
 
 
Figure 6: Kaplan Meier survival curve by HIV status (HIV seropositive vs HIV 
seronegative) 
 
Figure 12 shows the Kaplan Meier survival curve by HIV status. The figure shows an overlap 
between the two curves in the first 10 months showing that there was no difference in the survival 
probability of patients with HIV versus those without HIV. However, beyond 10 months, HIV 
seronegative patients with HL had a higher probability of survival than HIV seropositive patients 
with Hodgkin lymphoma. 
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Figure 7: Kaplan Meier survival curve by histological subtypes 
 
Figure 13 shows the Kaplan Meier survival curve by histological subtypes. Patients with 
lymphocyte depleted histological subtype had a higher probability of survival than those with other 
histological subtypes. However, the numbers were very small in this category, making the analysis 
less meaningful.  
 
 
 
 
 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
c
u
m
u
la
ti
v
e
 s
u
rv
iv
a
l
0 10 20 30 40
analysis time (months)
LDHL MCHL
NLPHL NSHL
Kaplan-Meier curve by histological subtype
61 
 
 
Figure 8: Kaplan Meier survival curve by ‘B’ symptoms 
Figure 14 shows the Kaplan Meier survival curve by ‘B’ - symptoms. The figure shows that 
patients without ‘B’- symptoms have a higher probability of survival as opposed to patients with 
‘B’- symptoms in the first 10 months. This pattern changes after 10 months where there is an 
overlap between the survival probability of patients with ‘B’- symptoms and those without. After 
30 months, the patients without ‘B’ - symptoms are likely to have a higher survival probability 
than patients with ‘B’- symptoms.  
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Figure 9: Kaplan Meier survival curve by comorbidity (present vs absent) 
 
Figure 15 shows the Kaplan Meier survival curve by co-morbidity. The figure shows an overlap 
between the two curves throughout the years showing that there was no difference in the survival 
probability of patients with co-morbidity compared to those with a co-morbidity. 
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Table 27: Median survival by clinical characteristics 
 
 
 
The above table shows the median survival estimates of the Hodgkin lymphoma patients based on 
various demographic and clinical characteristics.  
  
Characteristic 
  
Median survival  
(months) 
Range  
(months) 
Overall  21.5 1-43 
Age   
<40 years 18 1-40 
>40 years  28 4-43 
Disease stage    
early disease  24 9-42 
advanced disease 20.5 1-43 
HIV status    
positive  18.5 1-43 
negative  28 2-42 
Histological 
subtypes   
  Mixed cellularity   16 2-36 
  Nodular sclerosis   26 1-40 
  Lymphocyte rich    14.5 2-27 
  Lymphocyte depleted  34 20-43 
B symptoms   
present 21 1-43 
absent  22.5 8-45 
Comorbidity    
present  21 1-43 
absent  22 3-42 
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4.0 CHAPTER FOUR:  DISCUSSION 
 
4.1 Patient’s background in the study 
From January 2005 to December 2012 (8 years), a total of 167 newly diagnosed patients with HL 
were seen (approximately 21 new patients per year). This is higher than the number that was seen 
in a previous study by Fazel, 2012, conducted at CHBAH, during the period 1990 to 2004, where 
approximately 11 new patients per year were diagnosed with HL (20).  
Of the 167 patients, 17 were excluded due to inadequate/insufficient information/data. The 
remaining 150 patients were included in this study. Ninety three percent of the 150 patients were 
of black ethnicity, in keeping with the demographic at CHBAH. There were 84 males (56%) and 
66 females (44%), with a male to female ratio of 1.27:1. The median age of the patients was 37 
years, with a range of 15-78 years. The peak frequency was in the third and fourth decades of life. 
This is in contrast to the earlier study done at CHBAH, where the median age was 29 years, and is 
likely a reflection of the significantly higher contribution from HIV seropositivity (60% compared 
to 28%) (20). HIV seropositivity was noted in 90 patients (60%), while the remaining 60 patients 
(40%) were HIV seronegative.  
 
4.2 Clinical manifestations 
In general, our patients with HL present late, with advanced stage disease.  For the whole group 
of 150 patients, lymphadenopathy was the most common presenting feature (92.7%), with > 80%  
(82.7%) having lymphadenopathy in the classically described cervical area. ‘B’ symptoms were 
present in 74.7% of the patients. Advanced stage disease (stage III and IV) was noted in 74% of 
the patients and a performance status of  ≥2 was evident in 66.7% of the patients. Hepatomegaly 
was present in 62% while splenomegaly was noted in 37% of the patients. Bone marrow 
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involvement at presentation was present in 18.7% of the patients.  All these clinical features are 
consistent with late presentations and more advanced stage disease. 
 
4.3 Laboratory results  
More than 50% of the patients had anaemia at presentation. Thrombocytopenia was noted in 8% 
of the patients, while thrombocytosis (reactive) was evident in 24% of the patients. Leucopaenia 
and leucocytosis were uncommon, accounting for 4% and 2% of the patients respectively. 
Hypoalbuminaemia and an elevated LDH were both present in 40% of the patients, respectively.  
 
4.4 Histological subtypes of HL 
The most common histological subtypes of HL in the study were both Mixed cellularity classical 
HL and Nodular sclerosis classical HL, with 49 patients (32.7%) in each group. However, in the 
HIV seropositive group, MCcHL was the most common subtype (36 patients – 40%), compared 
to the NScHL subtype (21 patients – 33%). Conversely, in the HIV seronegative group, NScHL 
was more common than MCcHL, being present in 28 patients (46.6%), as compared to 13 patients 
(21.67%) with MCcHL. An unusual finding was the relatively large number of patients (i.e. 41 
patients – 27.3%), in whom the histological subtype was unclassifiable. This is an indication of an 
increasing number of patients being diagnosed in sites other than lymph nodes, such as the bone 
marrow and on liver biopsy. This form of diagnosis is more common in patients with HIV 
seropositivity.   
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4.5 Comorbid diseases  
Comorbid diseases other than HIV and TB were also encountered in this study group. The 
comorbid diseases include: hypertension, diabetes, stroke and connective tissue disorders. Of these 
diseases, hypertension (8 patients) and diabetes were the most common. As both these diseases 
predated the onset of HL and are common diseases seen in the general population, the association 
is likely to be coincidental. Corticosteroid therapy may have been implicated as being causative, 
if these conditions occurred as a complication of HL.  
 
4.6 Autoimmune haemolytic anaemia (AIHA) and HL 
Autoimmune haemolytic anaemia (AIHA) is rare in HL. It can occur before HL, during or after 
the diagnosis of HL. Patients with both AIHA and HL are generally older, with a male 
predominance. NScHL and MCcHL are the most common subtypes, where this association is 
encountered.  
Three patients had AIHA. Two of the patients were HIV seropositive. Of the three patients, two 
were diagnosed with AIHA prior to the diagnosis of HL, making the association unlikely.  
 
4.7 HL and Connective tissue disease   
The association of HL and connective tissue disease is rarely encountered. In our study, two 
patients had connective tissue diseases (CTD) in association with HL. This included one patient 
each with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Both the patients 
were diagnosed with their CTD prior to the diagnosis of HL, making the association unlikely.  
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4.8 HIV and HL  
The last decade has witnessed the emergence of Hodgkin lymphoma occurring with increasing 
frequency in association with HIV. The relative risk of acquiring HL is 10-20 fold higher with 
HIV seropositivity, compared to the general population. HIV associated Hodgkin lymphoma is 
generally more aggressive, presents with advanced stage disease, frequent ‘B’ symptoms, less 
favourable histology, more frequent bone marrow involvement and overall, a poorer prognosis 
compared to Hodgkin lymphoma in HIV seronegative individuals.  
A comparison of the HIV seropositive and HIV seronegative patients in our study reveals a 
statistically significant difference between the histological subtypes (mixed cellularity with HIV 
seropositivity (p=0.019) and nodular sclerosis with HIV seronegativity (p=0.002), TB association 
(higher with HIV seropositivity – p=0.001) and more bone marrow involvement with HIV 
seropositivity (p=0.0007). A poorer prognosis, with a shorter median survival was also noted in 
HIV seropositive individuals, compared to HIV seronegative individuals (see table 23).  
 
4.9 Hodgkin lymphoma and TB 
The association of TB and HL is well described (14, 20, 65, 66). The increased association is due 
to impaired cellular immunity that predisposes patients with HL to infections like HIV and TB 
(66). Depressed immunity can also be due to chemotherapy, including the use of corticosteroids, 
which may facilitate reactivation of dormant TB bacilli and dissemination of infection.  
Tuberculosis and HL share similar clinical features such as the presence of constitutional 
symptoms, lymphadenopathy, bone marrow infiltration and splenomegaly. Both conditions can 
coexist in the same patient. Lymph node and bone marrow samples may show evidence of both 
TB and HL. 
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An association of TB was noted in 39.3% of the patients in our study, with 79.7% of the patients 
having had a diagnosis of TB prior to lymphoma diagnosis and 20.3% of patients were diagnosed 
with TB after the lymphoma diagnosis. The association between TB and HL is not surprising in 
our patients and could be explained on a multifactorial basis – high prevalence of TB in the 
background population, high HIV seropositivity rate, concomitant chemotherapy and 
corticosteroid use.   
 
4.10 Treatment  
Of the 150 patients in the study, 87.3% received chemotherapy and 12.7% died prior to receiving 
chemotherapy. The most commonly used initial combination chemotherapy regime was ABVD 
(Adriamycin, bleomycin, vinblastine, decarbazine) and prednisone. The median number of cycles 
received was 7.5. However, some patients defaulted and others died before completing their 
planned number of cycles.  
Of the patients that received initial chemotherapy, 22 patients received less than 2 cycles of 
chemotherapy, 48 patients received 2 or more but less than 8 cycles of chemotherapy, and 61 
patients received 8 or more cycles of chemotherapy. 
In general, patients with early stage disease received 4-6 cycles of chemotherapy, while those with 
advanced stage disease received 6-8 cycles of chemotherapy. The patients who relapsed were 
given second line chemotherapy or considered for high dose chemotherapy followed by an 
autologous stem cell transplant (see tables 3.24 and 3.25). Of the 150 patients, 48 (32%) are alive, 
44 (29.3%) have died and 58 (38.7%) are lost to follow up. Understanding the nature of HL, it is 
likely that the majority of patients who are lost to follow are alive and in remission. 
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Table 28: Comparison of Dr Fazel’s study - 2012 and my study - 2017 
 
Variable for Comparison Fazel’s  Study - 2012 Turatsinze’s  study - 2017 
   
Time frame  14 years  8 years 
Institution CHBAH CHBAH 
Number of patients  163 150 
Gender ratio (M:F ratio) 1.3:1 1.27:1 
Median age 29 37 
Range 13-87 15-78 
HIV seropositivity 28% 60% 
Performance status 
        ≤ 2 
        > 2 
 
90% 
10% 
 
48% 
52% 
Presence of ‘ B’ symptoms 78% 74.7% 
Presence of lymphadenopathy  85% 92.7% 
Laboratory features   
      Anaemia 
     Thrombocytopenia   
     Leukopenia 
     Increased Albumin and LDH    
 
- 
- 
- 
- 
 
50% 
8% 
4% 
40% 
Histological subtypes:  
         Mixed cellularity cHL 
         Nodular sclerosis cHL 
         Lymphocyte Rich cHL 
         Lymphocyte depleted cHL 
         Unclassified 
 
45% 
37% 
3% 
0% 
15% 
 
32.7% 
32.7% 
2.7% 
4.6% 
27.3% 
Outcome          
    Alive  
    Died 
    Lost to  follow up 
 
9% 
31% 
60% 
 
32% 
29.3% 
38.7% 
Ann Arbor stage 
      0-1 
      ≥ 2 
 
5.13% 
94.87% 
 
7.3% 
92.7% 
Bone marrow involvement 26% 18.7% 
Tuberculosis in association with HL 32% 20.3% 
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4.11 Study limitations 
Since our study was a retrospective study, there were some limitations. These limitations 
include: 
 Inadequate and missing demographic and clinical data from  patient files 
 Inadequate and missing blood results, imaging and histology results in the patient files 
 Poor compliance and lost to follow up of patients  
 Information on treatment, follow up and response to treatment may not have been 
documented completely in all patients 
 Lack of availability of PET/CT scans at initial assessment and at follow up 
 Lack of the above information does impact on accurate assessment of treatment response, 
disease-free survival and overall survival. Moreover, the documentation of long term 
toxicities of therapy in a potentially curable malignancy may not be adequately reflected.  
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5. CHAPTER FIVE: CONCLUSION 
Hodgkin lymphoma in southern Africa is similar to what has been described in the literature, in 
regard to many salient features of the disease. However, in our study, there was a high   prevalence 
of HIV and TB, in association with HL. Over the past three decades, there has been a paraigm shift 
at our institution, from an early period in the 1980’s with no HIV seropositivity in association with 
HL, to <50% in the 1990’s and early 2000’s, to > 50% in the last decade. The association between 
HIV and HL has an impact on the adverse clinical presentation and poorer outcome of our patients.  
Health care workers need to be aware of this emerging and increasing association between HIV 
and Hodgkin lymphoma, so that patients could be diagnosed early and timeously, and both 
combination antiretroviral therapy and chemotherapy could be administered 
concurrently/simultaneously and without delay.  
The limitations with regard to the retrospective nature of this study have been mentioned in the 
last chapter. It is hoped that in future, prospective studies should be undertaken looking at various 
aspects of HL, including a more detailed study on the impact of HIV on HL.  
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APPENDIX A: DATA COLLECTION SHEET 
1. PATIENT STUDY NUMBER  
  
  
2. OCCUPATION (DOMINANT AND RELEVANT 
OCCUPATIONS) 
 
  
 
 
 
 
 
3. AGE  
  
4. GENDER        M  F  
  
5. ETHNIC 
GROUP      
BLACK  ASIAN  
     
 COLOURED  WHITE  
  
6. ECOG PERFORMANCE STATUS     1  2  3  4  
  
7. B  SYMPTOMS YES  NO  
  
IF 
YES: 
- Weight 
Loss 
 - Night sweats  - Fever >38˚C  
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8. SEVERE 
PRURITUS  
YES  NO  
  
9. COMORBID DISEASE (other than HIV or TB)  
  
YES                                    NO  
  
IF YES – SPECIFY NAME AND DURATION OF DISEASE  
  
  
  
10. RELEVANT MEDICATION/EXPOSURE PRIOR TO DIAGNOSIS (e.g. 
cytotoxic agents, radiation, petroleum toxins) 
 
  
YES                                     NO  
  
IF YES GIVE 
DETAILS 
 
  
  
  
  
11. LYMPHADENOPATHY AT PRESENTATION  
  
YES                                     NO  
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IF YES - 
DURATION 
 
  
  
12. HISTORY OF 
TUBERCULOSIS 
YES   NO  
  
- IF YES WHEN WAS THE DIAGNOSIS 
MADE? 
PRIOR TO  DIAGNOSIS   
  
                                   DURING LYMPHOMA 
TREATMENT 
   
  
                                   CURRENTLY                                               
  
 - HOW WAS TB DIAGNOSED  
   
 
 
 
 
 
 - SITE OF TB  
   
 
 
 
 
 - START DATE AND DURATION OF 
TREATMENT 
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 -   
  
13. CLINICAL FEATURES AT 
PRESENTATION 
 
  
PYREXIA
L 
 PALLOR  PETECHIAE  JAUNDICE  
  
OTHERS  SPECIF
Y 
 
    
 
 
 
14. BULK DISEASE YES  NO  
     
IF YES - PERIPHERAL  - CXR  
     
 SITE  SIZE  
     
 
 
 
15. LYMPHADENOPATHY AT PRESENTATION 
 
 
YES             NO  
     
              IF YES, SITE      
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16. EXTRA NODAL SITES AT PRESENTATION  
     
      YES OR NO     SITE
S 
 
     
  
- IF YES, DOCUMENT THE SITES, SIZE, SYMMETRY AND ALL THE OTHER 
RELEVANT CLINICAL CHARATERISTICS (E.G. CONSISTENCY, MOBILITY, 
TENDERNESS, OVERLYING SKIN ETC.) OF THE LYMPHADENOPATHY 
 
        MENTION ALL THE NEGATIVE PERIPHERAL SITES OF 
LYMPHADENOPATHY 
 
        MENTION IF THERE IS INVOLVEMENT OF WALDEYER’S RING, 
INTRATHORACIC INVOLVEMENT – SVC SYNDROME, DE’ESPIANS SIGN 
AND PEMBERTON’S SIGN, INTRA-ABDOMINAL DISEASE AND IN A MALE 
THE EXAMINATION OF THE SCROTUM AND TESTES  
 
 
17. INVOLVEMENT OF LIVER AND SPLEEN   
  
YES OR NO   
  
IF YES, GIVE DETAILS (SIZE, CHARACTERISTIC ETC.) 
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18. TRUE EXTRA NODAL SITES AT PRESENTATION (OTHER THAN LIVER, 
SPLEEN AND BONE MARROW) – SUCH AS CNS, SKIN, BONE, GIT ETC.  
  
YES OR NO         SITE AND DETAILS    
    
   
 
    
19. RADIOLOGICAL FINDINGS  
  
CXR  
  
  
 
 
 
 
SONAR  
  
  
 
 
 
 
CT SCAN  
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PET/CT 
SCAN  
 
  
  
 
 
  
MRI SCAN  
  
  
 
20. ANN ARBOR STAGING 
21.  
 
  
  1  2  3  4  A  B  
  
SUBSCRIPTS: ‘E’, ‘X’   
  
22. BONE MARROW ASPIRATE AND TREPHINE 
  
INVOLVEMENT, YES OR NO   
   
FINDINGS (MENTION OF ANY EVIDENCE OF TB, NON-SPECIFIC 
GRANULOMAS ETC.)  
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23. FNA OF NODE YES OR 
NO 
   
  
SITE   
 
   
FINDINGS   
 
   
24. SUMMARY OF HISTOLOGICAL FINDINGS  
   
SITE, TYPE OF TISSUE, FINDINGS, SPECIAL STAINS, SUBTYPE OF HL 
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25. HIV 
SEROLOGY 
- REACTIVE  - NON-REACTIVE 
 
  
IF REACTIVE, WHEN (MONTH, YEAR) WAS HIV DIAGNOSED? NOTE CD4 
COUNT AT PRESENTATION    
  
   
 
  
   
 
  
  
- IS PATIENT ON ARV’S? YE
S 
 NO  
  
- IF YES: REGIMEN  
   
   
  
 DATE OF COMMENCEMENT OF 
ARV’S 
 
   
   
  
 TREATMENT 
COMPLICATIONS 
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 FOLLOW UP CD4 COUNTS AND VIRAL 
LOAD 
 
   
   
  
   
  
RELATED, COMPLICATION OF TREATMENT, OTHER 
 
 
 
 
 
  
   
26. SURVIVAL  
  
- OVERALL SURVIVAL     
  
- DISEASE FREE 
SURVIVAL 
    
  
 
27. ANY OTHER RELEVANT INFORMATION  
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APPENDIX B: ANN ARBOR STAGING SYSTEM 
Ann Arbor Staging System with Cotswolds’ modification  
Stage Description 
I 
Involvement of a single lymph node region or lymphoid structure (e.g., spleen, 
thymus, Waldeyer's ring) 
II 2 or more lymph node regions on the same side of the diaphragm 
III Lymph nodes on both sides of the diaphragm 
III1 With splenic hilar, coeliac, or portal nodes 
III2 With para-aortic, iliac, or mesenteric nodes 
IV Involvement of extranodal site beyond that designated “E”  
Modifying features 
A No symptoms 
B Fever, drenching night sweats, weight loss >10% in 6 months 
X 
Bulky disease: greater than one third widening of mediastinum or >10 cm 
maximum diameter of nodal mass 
E Involvement of single, contiguous, or proximal extranodal site 
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APPENDIX C: ECOG PERFOMANCE STATUS 
 
GRADE ECOG PERFORMANCE STATUS 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work 
2 
Ambulatory and capable of all selfcare but unable to carry out any work activities; up 
and about more than 50% of waking hours 
3 
Capable of only limited selfcare; confined to bed or chair more than 50% of waking 
hours 
4 Completely disabled; cannot carry on any selfcare; totally confined to bed or chair 
5 Dead 
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APPENDIX D: RESPONSE DEFINITIONS FOR CLINICAL TRIALS            
 
Response Definition Nodal Masses Spleen, Liver Bone Marrow 
CR 
 
Disappearance of 
all evidence of 
disease 
(a) FDG-avid or PET 
positive prior to therapy; 
mass of any size permitted 
if PET negative (b) 
Variably FDG-avid or 
PET negative; regression 
to normal size on CT 
Not palpable 
nodules 
disappeared  
Infiltrate cleared on repeat 
biopsy; if indeterminate by 
morphology, 
immunohistochemistry 
should be negative 
PR 
 
Regression of 
measurable 
disease and no 
new sites 
 
≥ 50% decrease in SPD of 
up to 6 largest dominant 
masses; no increase in size 
of other nodes (a) FDG-
avid or PET positive prior 
to therapy; one or more 
PET positive at previously 
involved site   
(b) Variably FDG-avid or 
PET negative; regression 
on CT 
≥ 50% decrease in 
SPD of nodules (for 
single nodule in 
greatest transverse 
diameter); no 
increase in size of 
liver or spleen 
Irrelevant if positive prior to 
therapy; cell type should be 
specified 
SD Failure to attain 
CR/PR or PD 
(a) FDG-avid or PET 
positive prior to 
therapy; PET positive 
at prior sites of disease 
and no new sites on 
CT or PET    
 
(b) Variably FDG-avid 
or PET negative; no 
change in size of 
previous lesions on CT 
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Relapsed 
disease or 
PD 
Any new lesion or 
increase by ≥ 50% 
of previously 
involved sites 
from nadir 
Appearance of a new 
lesion(s) > 1.5 cm in any 
axis, ≥ 50% increase in 
SPD of more than one 
node, or ≥ 50% increase 
in longest diameter of a 
previously identified 
node > 1 cm in short axis 
Lesions PET positive if 
FDG-avid lymphoma or 
PET positive prior to 
therapy 
 
> 50% increase 
from nadir in the 
SPD of any 
previous lesions 
 
New or recurrent 
involvement 
 
 
Abbreviations: CR, complete remission; FDG, Fluorodeoxyglucose; PET, positron emission tomography; 
CT, computed tomography; PR, partial remission; SPD, sum of the product of the diameters; SD, stable 
disease; PD, progressive disease. 
 
